Evidence map›Paper›PMID 34706132›Full record

ArticleCancer science2022

Hsa_circ_0005576 promotes osimertinib resistance through the miR-512-5p/IGF1R axis in lung adenocarcinoma cells.

Suo Liu, Zhibin Jiang, Peng Xiao, Xiaozhi Li, Yinji Chen, Hao Tang, Yanfei Chai, Yicai Liu, Zhao Zhu, Qianyi Xie and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 36 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Receptor tyrosine kinase inhibitors in cancer.Cellular and molecular life sciences : CMLS · 2023
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Suo LiuDepartment of Cardiothoracic Surgery, The Third Xiangya Hospital of Central South University, Changsha, China.ORCID https://orcid.org/0000-0001-6765-3485
Zhibin JiangDepartment of Cardiothoracic Surgery, The Third Xiangya Hospital of Central South University, Changsha, China.
Peng XiaoDepartment of Cardiothoracic Surgery, The Third Xiangya Hospital of Central South University, Changsha, China.
Xiaozhi LiDepartment of Cardiothoracic Surgery, The Third Xiangya Hospital of Central South University, Changsha, China.
Yinji ChenDepartment of Cardiothoracic Surgery, The Third Xiangya Hospital of Central South University, Changsha, China.
Hao TangDepartment of Cardiothoracic Surgery, The Third Xiangya Hospital of Central South University, Changsha, China.
Yanfei ChaiDepartment of Cardiothoracic Surgery, The Third Xiangya Hospital of Central South University, Changsha, China.
Yicai LiuDepartment of Cardiothoracic Surgery, The Third Xiangya Hospital of Central South University, Changsha, China.
Zhao ZhuDepartment of Neurosurgery, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Qianyi XieDepartment of Radiology, The Third Xiangya Hospital of Central South University, Changsha, China.
Wei HeDepartment of Pediatrics, The Third Xiangya Hospital of Central South University, Changsha, China.
Yuchao MaDepartment of Cardiothoracic Surgery, The Third Xiangya Hospital of Central South University, Changsha, China.
Longyu JinDepartment of Cardiothoracic Surgery, The Third Xiangya Hospital of Central South University, Changsha, China.ORCID https://orcid.org/0000-0003-2032-5569
Wei FengDepartment of Cardiothoracic Surgery, The Third Xiangya Hospital of Central South University, Changsha, China.ORCID https://orcid.org/0000-0003-0065-6539
Central South University · CN

Funding

Hunan Province Natural Science Foundation 2018JJ3777Hunan Province Science and Health Union Foundation 2018JJ6053Hunan Province Science and Health Union Foundation 2018JJ6135
6 · The paper itself

Abstract

Osimertinib is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) for lung adenocarcinoma (LUAD) harboring activating mutations, but patients ultimately develop acquired resistance. Circular RNAs are involved in EGFR-TKI resistance, while the role of hsa_circ_0005576 in the osimertinib resistance of LUAD remains unknown. In this study, we demonstrated that hsa_circ_0005576 could facilitate osimertinib-resistant LUAD cells. Briefly, knockdown of hsa_circ_0005576 not only suppressed the proliferation and promoted the apoptosis of resistant LUAD cells, but also increased their sensitivity to osimertinib. Mechanistically, hsa_circ_0005576, serving as an miRNA sponge, could directly interact with miR-512-5p and subsequently upregulate the miR-512-5p-targeted insulin-like growth factor 1 receptor. Rescue assays indicated that miR-512-5p inhibition could reverse the effects of hsa_circ_0005576 knockdown in LUAD cells resistant to osimertinib. Overall, our study revealed that hsa_circ_0005576 regulates proliferation and apoptosis through miR-512-5p/IGF1R signaling, which contributes further to the resistance of LUAD cells to osimertinib. In addition, this study provides a novel insight into the mechanisms underlying osimertinib resistance of LUAD.

Indexed as

Drug Resistance, NeoplasmAcrylamidesAdenocarcinoma of LungAniline CompoundsAnimalsCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansIndolesLung NeoplasmsMiceMicroRNAsNeoplasm TransplantationPyrimidinesReceptor, IGF Type 1AcrylamidesAniline CompoundsIGF1R protein, humanIndolesMicroRNAsMIRN512 microRNA, humanosimertinibPyrimidinesReceptor, IGF Type 1RNA, Circularhsa_circ_0005576IGF1Rlung adenocarcinomamiR-512-5posimertinib resistance

Identifiers

PMID34706132
PMCPMC8748248
OpenAlexW3208129644

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.